Prospective study of 197 cancer patients reports 84.4% clinical benefit rate with ivermectin and mebendazole combination
By
NICOLAS HULSCHER
Summary
This prospective observational cohort study analyzed 197 cancer patients prescribed a combination of ivermectin and mebendazole off-label via a U.S. telemedicine platform. At six-month follow-up (122 participants completed), the study reported a Clinical Benefit Ratio of 84.4%, with 48.4% of participants reporting tumor regression or no evidence of disease, 36.1% stable disease, and 15.6% progression. Adherence was high (86.9% completed initial prescription), side effects were predominantly mild and gastrointestinal (25.4% reported), and 93.6% continued therapy after dose adjustment. The authors conclude the findings are hypothesis-generating and support the need for randomized controlled trials.
Source
Twitter / XProspective study of 197 cancer patients reports 84.4% clinical benefit rate with ivermectin and mebendazole combinationar.iiarjournals.orgKey quotes
· 5 pulledThe Clinical Benefit Ratio (CBR) was 84.4% (95% confidence interval=77.0-89.8%).
At follow-up, 48.4% of participants reported tumor regression or no evidence of disease (32.8% NED; 15.6% regression), while 36.1% reported stable disease and 15.6% reported progression.
Side effects, reported by 25.4%, were dose-dependent and predominantly mild and primarily gastrointestinal, with 93.6% continuing therapy after adjustment.
These findings are hypothesis-generating and support the need for randomized controlled trials.
Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies.
You might also wanna read
Study Shows Ivermectin Reduces Malaria Infections by 26% in Children
A new study by KEMRI-Wellcome Trust researchers reveals that ivermectin, a drug typically used for neglected tropical diseases, reduced new
ndm.ox.ac.uk·11mo ago
Johns Hopkins Study Finds Anti-Parasitic Drug Slows Pancreatic Cancer in Mice
Johns Hopkins Medicine researchers have discovered that an anti-parasitic drug can prevent the initiation, progression, and metastasis of pa
hopkinsmedicine.org·8d agoIncyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
Experimental once-daily drug doubles survival rates for pancreatic cancer patients
An experimental once-daily drug shows promising results in treating pancreatic cancer, doubling survival rates by slowing disease progressio
to.pbs.org·29d ago
Experimental pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients
Researchers reported that daraxonrasib, a novel daily pill, helped people with advanced pancreatic cancer live longer by blocking a mutated
abcnews.com·28d ago
Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial
A new experimental pill called daraxonrasib has shown promising results in extending survival for patients with advanced pancreatic cancer.
cnbc.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.